Introduction
DNA from integrated retrovirus is found interspersed in the human genome and represents about 4.2% of our total chromosomal DNA. Of this, 8% is composed of human endogenous retroviral elements (HERV; ref. 1) that integrated into the human genome 1 to 5 million years ago. Transcriptional activity of the envelope (env) and polymerase proteins appears to have remained intact (2, 3), although HERVs do not apparently produce infectious virions, are poorly expressed in somatic cells, and are not expressed in other species (4) . Stressors such as exposure to UV light and hormones (e.g., estrogen and progesterone) can increase transcriptional activity of HERV-K in tumor cells (2, 5) . Approximately half of HERV-K long terminal repeats (LTR) found in the human genome initiate transcription of nonrepetitive coding regions, of which 30% of their gene products bind p53, suggesting a role in oncogenesis (6) . Expression of the HERV-K env protein is upregulated on infected cells (e.g., HIV-infected T cells; ref. 7) and tumor cells including breast cancer (8) , ovarian cancer (9) , lymphoma (10), teratocarcinoma (11) , and melanoma (12, 13) . During the early stages of melanoma transformation, HERV-K mRNA can be induced via the BRAF-MEK-ERK signaling pathway and epigenetic changes associated with p16INK4A-CDK4 (12) . Expression of HERV-K env positively correlates with progression of primary melanoma to those with metastatic potential (13) .
Adoptive transfer of genetically modified T cells redirected to tumor-associated antigens (TAA) has shown promise, although most of the clinical trials report on the therapeutic benefit from targeting hematologic malignancies. These therapies include a portfolio of T cells genetically modified to express (i) T-cell receptor (TCR) that recognizes TAA in the context of HLA (14) or (ii) a chimeric antigen receptor (CAR) specific for a TAA independent of HLA (15) . Clinical trials infusing nongenetically modified T cells include melanoma-specific tumor-infiltrating lymphocytes (TIL) for the investigational treatment of advanced-stage melanoma and have yielded favorable objective responses (16) . This approach requires autologous tumor cells that process and present TAAs on HLAs in sufficient numbers to be recognized by endogenous specific TCRs (17) . The ex vivo genetic modification to enforce expression of melanoma-specific CAR on T cells derived from peripheral blood is one approach to bypass the need to harvest tumor cells and overcome immune tolerance.
We and others have designed CD19-specific CARs for the investigational treatment of B-cell malignancies that are currently being evaluated in clinical trials (18) . We express our CD19-specific CARs on T cells using a nonviral approach to gene transfer based on the Sleeping Beauty (SB) transposon/ transposase system (19) . T cells stably expressing the introduced CAR are selectively propagated on g-irradiated artificial activating and propagating cells (AaPC) derived from K-562 cells (20) . The 2 platform technologies of SB system and AaPC have been successfully used to generate CAR þ T cells for ongoing clinical trials (15) . We now report the successful generation of HERV-K envspecific CAR þ T cells using the SB system and their numeric expansion on HERV-K þ AaPC. In vitro, HERV-K env-specific CAR þ T cells lysed tumors cells expressing HERV-K env on the cell surface. These CAR þ T cells were also able to detect HERV-K env shed from the tumor cell surface. In vivo, infusion of HERV-K env-specific CAR þ T cells decreased tumor burden in a mouse model of metastatic melanoma. These data suggest that adoptive transfer of HERV-K env-specific CAR þ T cells is a promising therapeutic strategy for melanoma.
Materials and Methods
Generation and expansion of HERV-K env-specific CAR þ T cells
Generation and expansion of HERV-K env-specific CAR þ T cells were performed using a protocol previously described (20) . Briefly, the 2 Â 10 7 peripheral blood mononuclear cells (PBMC) were washed and rested in complete RPMI supplemented with 10% FBS (Thermo Scientific) and 1% GlutaMAX (Gibco Life technologies) for 2 hours. On day 0, these cells were then resuspended in 100 mL of Nucleofector solution (Human T-cell Kit; Lonza), with supercoiled DNA coding for HERV-K envspecific CAR transposon (15 mg CoOp 6H5CARCD28/pSBSO) and supercoiled DNA coding for SB transposase (5 mg pCMV-SB11) and transferred to a single cuvette and electroporated using the U-14 program (Lonza). The electroporated T cells were rested for 4 hours at 37 C in complete phenol red-free RPMI (Thermo Scientific), after which a half-media change was performed. The K562-derived clone 4 expresses endogenous HERV-K env (Supplementary Fig. S2A ) and thus serves as AaPC to propagate HERV-K env-specific CAR þ T cells. The electroporated T cells cultured in RPMI containing 10% FBS were supplemented with g-irradiated (100 Gy) K562-AaPC at a 1:2 T cell/AaPC ratio on day 1. Irradiated AaPC were re-added at the end of every week for T-cell stimulation at the same ratio. Cell lines and their propagation A375, A624, and A888 were a gift from Dr. Lazlo Radvanyi (MDACC, Houston, TX); EL4 parental was obtained from ATCC (catalog # TIB-39); and A375-SM (super-metastatic melanoma cell line) was received from the Characterized Cell Line Core Facility (CCCF) at MDACC. All cell lines were obtained in the year 2010 during study initiation and were cultured in complete RPMI (Thermo Scientific) with 10% FBS (Thermo Scientific) and 5% GlutaMAX (Gibco Life technologies). All cell lines were authenticated by MDACC DNA Sequencing and Analysis Core using DNA profiling of short tandem repeat markers and further verified by morphology and/or flow cytometry. They were routinely tested negative for mycoplasma.
6H5 mAx
To measure the HERV-K env expression on tumor cell surface, we developed a 6H5 mAx specific for the HERV-K env antigen. 6H5 mAx represents soluble CAR by swapping the CD28 and CD3z endodomain with a polyhistidine tag (Supplementary Fig. S3A ). This construct was inserted into a DNA plasmid coding for lentiviral vector ( Supplementary Fig. S3B ) that was introduced into 293 METR cells (gift from Dr. Brian Rabinovich) using Lipofectamine 2000 (Life Technologies), and conditioned supernatant was concentrated using 100-kDa cutoff centrifugal filter (catalog # UFC910024; EMD Millipore). The 6H5 mAx was then purified using a polyA column (Life Technologies) and analyzed on a SDS-PAGE gel to confirm purity.
Translational Relevance
Patients with metastatic melanoma have a poor prognosis due to resistance to conventional therapies such as chemotherapy, radiation, and surgery. We use a non-viral gene therapy method whereby T cells are engineered to express HERV-K envelope (env)-specific CAR. Our preclinical data suggest that we can specifically target and kill tumor cells expressing HERV-K env antigen while not attacking the normal cells. This therapy has implications for the treatment of human diseases beyond melanoma. HERV-K env is expressed on tumor cells derived from hematologic malignancies and solid tumors as well as after infection such as CD4 T cells bearing HIV. This provides an attractive opportunity that one CAR design targeting HERV-K env to be used to treat a variety of disease states. HERV-K env-specific CAR þ ffLuc þ T cells on days 7, 14 and 21. 6 Â 10 4 U IL-2 (eBioscience) was injected intraperitonealy (i.p.) on day of each T-cell infusion and twice on the day after. One cohort of mice (n ¼ 6) bearing the tumor received no treatment, whereas a control group of mice (n ¼ 5) without tumor received a similar number of CAR þ T cells as in treatment group. Bioluminescence imaging (BLI) on mice in anterior-posterior position was performed weekly using a Xeno IVIS 100 series system (Caliper Life Sciences) to reveal the distribution and quantity of tumor and T cells as previously described (22) . Mice were anesthetized and placed in for BLI. To measure the HERV-K env-specific CAR þ ffLuc þ T-cell activity 150 mL (200 mg/mouse) of D-luciferin potassium salt (Caliper Life Sciences) was injected intraperitoneally. Ten minutes after injection, emitted photons were quantified using the Living Image 2.50.1 (Caliper Life Sciences) program.
In vivo
To image the tumor cell activity, 100 mL (60 mmol/L final concentration) of EnduRen (Promega) was injected intraperitoneally. Twenty minutes after injection, the tumor activity was quantified similar to ffLuc. This experiment was performed twice and the unpaired Student t test was performed to establish statistical significance of the photon flux. Livers from tumor alone and treatment groups were isolated on day 25 and imaged directly for mKate expression using a Leica M205FA stereo microscope and quantified for number of metastatic foci on the liver.
Results
Tumor-specific expression of HERV-K env on primary melanoma The 6H5 HERV-K env-specific monoclonal antibody (mAb; ref. 23 This mAb was used to interrogate expression of HERV-K env on and in primary (stages I through IV) and metastatic melanoma and normal skin. Punctate cell surface expression (solid arrow) and diffuse cytoplasmic staining (dotted arrow) were observed in tumor cells in a mutually exclusive manner (Fig. 1A) . IHC staining (scored from 0 to 3) on primary melanoma tissues were graded on the basis of intensity of staining for HERV-K env (Fig. 1B ). An H-index was calculated by multiplying the percentage of HERV-K env þ cells with the intensity of staining compared with the isotype control (24) . The average H-index for melanoma was 9.2 (n ¼ 220, SEM ¼ 2.4), which was 206-fold greater (P < 0.001) than benign skin tissue sampled from patients with melanoma S1C ). To determine whether HERV-K env expression was restricted to tumor cells, tissues from 29 types of healthy organs from 3 different donors were also assessed by IHC. We observed apparent absence of HERV-K env protein expression from these samples including normal skin (Fig. 1D ). In contrast, HERV-K env was observed on tumor cells originating from multiple anatomic sites ( Supplementary Fig. S1D ). These data support our contention that HERV-K env is a TAA and that as it is expressed on the cell surface, it may be targeted by HERV-K env-specific CAR þ T cells.
Generation and characterization of HERV-K env-specific CAR derived from 6H5 mAb We engineered a CAR with specificity for HERV-K env based upon the V H (at amino terminus) and V L domains derived from the 6H5 mAb that were joined via the Whitlow linker to form a single-chain variable fragment (scFv). This was fused in frame to a modified human IgG4 hinge/Fc (25) stalk, CD28 transmembrane domain, and a combination of CD28 and CD3z intracellular domains. This design is similar to our second-generation CD19-specific CAR (designated CD19RCD28) currently used in clinical trials (20) . We stably expressed this CAR on T cells derived from PBMC using the SB transposon/transposase system ( Fig. 2A) . HERV-K env-specific CAR þ T cells were then selectively propagated on AaPC (ref. 26 ; designated clone 4) derived from K-562 cells that express endogenous HERV-K env and were previously genetically modified by lentivirus transduction to coexpress CD64, CD86, CD137L, and a first-generation membrane-bound IL15 (Supplementary Fig. S2A ; ref. 20) . Control T cells from PBMC were (i) mock electroporated without DNA ("no DNA control") and expanded on AaPC clone 4 preloaded via transgenic CD64 with a CD3-specific mAb (OKT3) and (ii) CD19-specific CAR þ T cells generated per published method for our clinical trials (20) . About 95% of the electroporated/propagated T cells stably expressed the HERV-K env-specific CAR on their cell surface after 28 days of coculture with AaPC in the presence of soluble recombinant IL2 and IL21 (Fig. 2B) . Compared with CD19-specific CAR þ T cells, no appreciable difference was seen in
and (iii) ratio of CD4 þ to CD8 þ T cells ( Supplementary Fig. S2B) or ratio of expression of CAR to CD3 T cells ( Supplementary Fig.  S2C ). The average copy number of integrated transposon was 1.6 (n ¼ 3; SD, 0.03) per T-cell genome based on a Jurkat cell clone with a single integration of CAR (ref. 27 ; Fig. 2E ). This appears less than that reported after virus-mediated transduction of T cells to express a CAR (28) . We evaluated the therapeutic potential of the T cells (n ¼ 4) using multiparameter flow cytometry, which revealed the percentage of CAR þ T cells with na€ ve þ HERV-K env-specific CAR þ T cells (98.17% AE 2.3%, n ¼ 4) suggesting that these cells should be cytotoxic (Fig. 2F) . In addition to flow cytometry, we used a set of 500 bar-coded probes to digitally count mRNA molecules to reveal selected gene expression. Compared with no DNA control T cells (n ¼ 3), the HERV-K env-specific CAR þ T cells (n ¼ 3) had significantly (P < 0.5) increased levels of mRNA species coding for (i) chemokines and receptors (CCR1, CCR5, CCL3, and CCL4; ref. 30) , (ii) transcriptional regulators (LRP5, PAX5, TCF7), (iii) T-cell activators (CD80, RORA, KIR3DL2), and (iv) genes participating in lysis (perforin1 and granzyme H) suggesting that the HERV-K envspecific CAR þ T cells are capable of producing an effective response against the target TAA ( Supplementary Fig. S2E ). In aggregate, these data demonstrate that T cells could be modified with the SB system to express a CAR from 6H5 and propagated on HERV-K env þ AaPC generating a biologic product with therapeutic potential for melanoma.
Generation and characterization of HERV-K env-specific maxibody derived from 6H5 mAb To help define the specificity of the CAR derived from 6H5, we generated a soluble version of this immunoreceptor as a maxibody (mAx; ref. 31). The mAx is a soluble immunoreceptor that approximates the membrane-bound immunoreceptor as it is based CAR design, but lacks sequence anchoring it to the cell membrane. Indeed, the HERV-K env-specific 6H5 mAx consisted of the 6H5 scFv (used to generate the CAR) fused to full-length human IgG4 using the same modified hinge and Fc region used in the CAR construct ( Supplementary Fig. S3A and S3B). We evaluated cell surface expression of HERV-K env on EL4, AaPC clone 4, A888, A375-SM, and A624 cells using 6H5 mAb (Fig. 3A) and 6H5 mAx (Fig. 3B ). There was a positive trend between the H-indices calculated using 6H5-derived mAb and mAx at 3 different time points (days 1-3 after plating the cells on day 0; Spearman correlation coefficient, r ¼ 0.5, P ¼ 0.06; Fig. 3C ). Despite the variation in binding efficiency of 6H5 mAx and 6H5 mAb due to structural differences, the correlation plot indicates that these 2 soluble species apparently recognize the same TAA. We also performed an ELISA and observed a comparable level of binding of 6H5-derived mAb and mAx to plate-bound purified recombinant HERV-K env antigen, designated K10 (ref. 23 ; Fig. 3D ). K10 was expressed as a fusion protein with glutathione S-transferase and purified as previously described (8) . CD19-specific mAb (Fig. 3D) and plate-bound CD19 antigen were used as a negative control (Supplementary Fig. S3C ). As both soluble reagents inhibit the binding of each other, the mAb and mAx thus appear to bind to a shared epitope on K10 (Supplementary Fig. S3D ). Taken together, the 6H5-derived mAb and mAx appear to recognize HERV-K env lending support to the concept that the CAR expressed on T cells will also recognize this TAA in an antigen-specific manner.
Specificity of CAR þ T cells for HERV-K env
The redirected effector function of CAR þ T cells was evaluated to establish specificity for HERV-K env. We modified HERV-K env neg EL4 cells to express HERV-K env (Supplementary Fig. S4A ) to serve as targets (Fig. 4A) . HERV-K env-specific CAR þ T cells specifically killed HERV-K env þ EL4, but not parental EL4 cells (Fig. 4B) . HERV-K env-specific CAR þ T cells also mediated lysis of melanoma cells expressing endogenous HERV-K env. Compared with no DNA control T cells, killing of melanoma cell lines A888, A624, A375, A375-SM, which are recognized by 6H5, was significantly greater using HERV-K env-specific CAR þ T cells (P < 0.001; Fig. 4C ). CD19-specific CAR þ T cells served as an additional negative control and as expected failed to lyse A888, A375-SM, A624, and CD19 neg EL4 tumor cells above background. However, the CD19-specific CAR þ T cells exhibited specific lysis of melanoma and EL4 cells genetically modified to express CD19 antigen (ref. 22; Supplementary Fig. S4B and S4C ). These control data reveal that the apparent absence of an allo-mediated killing effect by CAR þ T cells targeting melanoma tumor cells. Although the cell surface expression of HERV-K env varied at different time points during cell culture (days 1-3 after plating the tumor cells on day 0) as assessed using 6H5mAx by flow cytometry (Fig. 4D ), we observed a positive correlation between lysis of melanoma cell lines by HERV-K env-specific CAR þ T cells and the density of HERV-K env expression on the tumor cell surfaces as calculated using H-index on (r ¼ 0.68, P < 0.001; Supplementary Fig. S4D ). To further assess the specificity of the HERV-K-specific CAR, a lentivirus encoding HERV-K env-specific shRNA was transduced into A888 cells to knockdown (KD) the TAA (designated A888 KD). Immunoblot analysis showed a decrease of approximately 50% HERV-K env expression compared with a scrambled shRNA control (Supplementary Fig. S4E ). We observed a 3-fold decrease in killing of A888 KD compared with parental A888 cells (Supplementary Fig. S4F ).We also examined the redirected lysis by HERV-K env-specific CAR þ T cells by video time-lapse microscopy specific CAR þ T cells was 2.9-, 5.1-, 5.9-, and 2.6-fold greater when incubated with A888, A375, A375-SM, and A624, respectively (Fig. 4F) . These data reveal that CAR þ T cells are specifically activated for killing and cytokine effector functions by HERV-K env.
HERV-K env is shed and can be detected by HERV-K envspecific CAR þ T cells
Because the percentage of HERV-K env expression appeared to vary at different time points when cultured tumor cells were analyzed by flow cytometry (Fig. 4D) , we assessed whether cell surface expression of this TAA was modulated as a result of shedding and reattachment over time. Western blot analysis (under reducing condition) of the concentrated supernatant from culture of tumor cells (HERV-K env þ A375-SM, A375, A888, clone 4, and HERV-K env neg EL4) probed with 6H5 mAb revealed a single band at 55 kDa consistent with cleaved HERV-K env lacking the transmembrane domain (in contrast to the 66-kDa band observed from the whole tumor cell lysates, which includes the surface and the transmembrane domains; ref. 10; Fig. 5A ). Preincubation of the 6H5 mAb with soluble K10 for 1 hour at 37 C reduced the intensity of staining on the blot, supporting our contention that the band detected in the cultured supernatant was HERK-K env (Fig. 5B) . A similar band was not was observed in the flow through after concentrating conditioned supernatant through a 100-kDa filter suggesting that shed nondenatured HERV-K env is more than 100 kDa in size (Fig. 5C ). We investigated whether concentrated media from A375-SM could block the ability of HERV-K env-specific CAR þ T cells to target A375-SM tumor cells. This conditioned supernatant, compared with media collected without exposure to tumor cells, resulted in approximately 80% reduction in tumor lysis (P < 0.05; Fig. 5D ). We also analyzed whether the shed TAA could trigger a response by genetically modified T cells. HERV-K env-specific CAR þ T cells produced 13-fold increase in IFNg when cocultured with parental EL4 cells upon exposure to concentrated supernatant collected from AaPC clone 4. This cytokine production was evaluated compared with concentrated supernatant from cultured EL4 cells or when control CD19-specific CAR þ T cells were used as effectors (P < 0.001; Fig. 5E ). As the shed TAA used in these experiments was concentrated, it is likely above physiologic levels for IHC staining of tumor samples did not reveal shed TAA or presence of HERV-K env expression in benign tissues surrounding tumor cells. These data indicate that HERV-K env protein is apparently present in supernatant concentrated from cultured tumor cells; however, the physiologic relevance of this observation and impact on ability of CAR þ T cells to recycle effector functions remains to be determined.
Reduced primary tumor and metastatic burden after infusion of HERV-K env-specific CAR þ T cells
We investigated whether the antimelanoma activity observed in vitro could be extended to an in vivo mouse model. T cells coexpressing firefly luciferase (ffLuc) and HERV-K env-specific CAR were generated by "double transposition" using the SB system (Supplementary Fig. S5A; ref. 33) . The growth kinetics, cytotoxicity, and specificity of HERV-K env-specific CAR þ ffLuc þ T cells and HERV-K env-specific CAR þ T cells were not significantly different (P > 0.05; Supplementary Fig. S5B and S5C ). Next, we developed a xenogenic NSG mouse model of metastatic melanoma in which A375-SM tumor cells (21) were genetically modified to coexpress Renilla luciferase 8.6535 (rLuc) and mKate S158A fluorescent protein (34) from a bicistronic vector (A375-SM-RmK) and intravenously injected (defined as day 0; Supplementary Fig. S5D ). Following tumor cell engraftment in lung and metastasis to liver, 2 Â 10 7 HERV-K env-specific CAR þ ffLuc þ T cells were intravenously administered with IL2 (Supplementary Fig. S5E ). BLI was used to serially measure rLuc-derived tumor burden on days 3, 10, 17, and 25 ( Fig. 6A) . Localization of HERV-K env-specific CAR þ ffLuc þ T cells was assessed the day after each T-cell injection. We monitored HERV-K env-specific CAR þ ffLuc þ T cell activity on days 7, 13, and 20 ( Supplementary Fig.   S5F ). Twenty-five days after injection of tumor, we observed 4.7-fold increased rLuc activity in untreated tumor bearing mice compared to mice with tumor receiving HERV-K env-specific CAR Fig. S5H ), and we used optical imaging at necropsy to observe a 75% reduction in fluorescent tumor colonies in the livers of the T-cell treatment group versus the untreated group (P < 0.05; Fig. 6C and D) . These data indicate that genetically modified CAR þ T cells can be used to treat mice with disseminated HERV-K env þ tumor.
Discussion
The env protein from an endogenous retrovirus may represent an attractive TAA for CAR-mediated T-cell therapy. This is based on our demonstration that melanoma, but not normal tissues, expresses HERV-K env protein and that a HERV-K env-specific CAR can recognize this TAA in vitro and in vivo.
The 6H5 mAb was used to evaluate the cellular expression of HERV-K env. We observed that only tumor cells (cell lines and primary biopsy material) express HERV-K env in contrast to benign skin from the same patients. Furthermore, the transition from primary to metastatic melanoma was associated with increased expression of this TAA. This supports results by others that high HERV-K env levels correlates with increased metastatic capacity (35) . Two distinct patterns of expression of this TAA were observed. Punctate and diffuse distribution of HERV-K env was found in the cell membrane and cytosol, respectively. Punctate staining may be associated with HERV-K env protein involved in (i) recycling of the HERV-K env between endosomes and the cell membrane, (ii) budding of exosomes, and/or (iii) packaging of virions. The latter 2 phenomena may aid in detachment and metastasis of tumor cells to distant anatomic sites (36) (37) (38) .
In addition to detecting HERV-K env on and in tumor cells, we also found this TAA in conditioned and concentrated supernatant harvested from tumor cells. Although HERV-K env could be concentrated using a 100-kDa filter, we assume that the shed HERV-K is either oligomerized or associated with other proteins that are dissociated when denatured to its 55-kDa form. However, immunoprecipitation of this protein for mass spectrometric analysis with 6H5 mAb or 6H5 mAx did not yield data indicating other proteins complexed with HERV-K env (data not shown). Endogenous retroviral particles are capable of extruding or budding from the tumor cell membrane as immature provirus (39, 40) . Indeed, shed HERV-K env is present in human plasma of patients with lymphoma and breast cancer (10) . The shed HERV-K env is likely incapable of binding or infecting normal cells surrounding the tumor due to presence of multiple stop codons (39, 40) . In vitro we could show that HERV-K env was recognized by CAR þ T cells and this interfered with the ability to target this TAA on tumor cells. However, this was under conditions when the shed TAA was concentrated. This is in contrast to our observations in vivo when the adoptive transfer of CAR þ T cells resulted in an antitumor effect. HERV-K env has been described on and in other tumor cells including breast cancer, ovarian cancer, prostate cancer, lymphoma, renal cell carcinoma, teratocarcinoma, and infected T cells during AIDS and thus has been studied as a target antigen for developing new treatment strategies (7) (8) (9) (10) (11) (41) (42) (43) . For example, 6H5 mAb against HERV-K env expressed on breast cancer cells produced a 10-fold reduction in tumor volume in a breast cancer mouse model (23) . Prophylactic vaccination against HERV-K env precluded the formation of renal cell carcinoma tumor and subsequent metastasis in mice (43) . HERV-K env-specific CD8 þ T cells obtained from patients with HIV were found in vitro to cross-react and eliminate HIV-infected cells in an antigenspecific manner (7) . Furthermore, anti retroviral drugs such as efavirenze and RNA interference (RNAi) of HERV-K retroviral element also reduced the growth and tumorigenic potential of melanoma in a mouse model (44) . A 4-fold increase in HERV-K þ melanoma tumor cell lysis was observed using HERV-K envspecific TCR expressed on T cells compared with HERV-K neg melanoma cell line in vitro (45) .
Our work using the SB system is a nonviral approach that uses a transposon (encoding CAR) and transposase (responsible for genome integration) that is suitable for clinical translation. We were able to selectively propagate HERV-K envspecific CAR þ T cells on AaPC along with IL2 and IL21 to numbers similar to CD19-specific CAR þ T cells used in our trials for the treatment of B-lineage malignancies (15) . About 50% of propagated HERV-K env-specific CAR þ T cells were of effector memory phenotype, previously shown to be more effective in vivo than other T-cell phenotypes, such as short lived effector T cells (46) . These HERV-K env-specific CAR þ T cells lysed tumor cells in an antigen-specific manner in vitro and in vivo implying the specificity of the CAR þ T cells to target HERV-K env protein. Thus, targeting the envelope protein HERV-K by CAR þ T cells may constitute a broad-based immunotherapeutic option for multiple cancers including solid and hematologic tumors and infectious diseases such as AIDS.
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